Design
Review
Authors
Loading...
Proposed betaARK1 reduction remains investigational in HF; leaves open whether targeted inhibition can restore beta-adrenergic signaling.
Key points are not available for this paper at this time.
Dong‐Ju Choi (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: